Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | Director | June 18, 2025 | July 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date June 18, 2025 · Filed July 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2025-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-18 · Grant · Acquired 30,000 · Balance 30,000 F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2025 Filed Jul 18, 2025 16:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-026411 · form4.xml · nonDerivative · entry 1 Pratumsuwan Piratip · CIK 0002055179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · security: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 19:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 22,443 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001140361-25-003241 · form4.xml · derivative · entry 2 Pratumsuwan Piratip · CIK 0002055179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,443 Underlying: Common Stock · 22,443 shares Expires 2035-02-03 F2 · derivative.exercise_date: This option represents a right to purchase a total of 22,443 shares of the Issuer's common stock, which will fully vest on February 3, 2026. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 19:47 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 51,181 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0001140361-25-003241 · form4.xml · derivative · entry 1 Pratumsuwan Piratip · CIK 0002055179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,181 Underlying: Common Stock · 51,181 shares Expires 2035-02-03 F1 · derivative.exercise_date: This option represents a right to purchase a total of 51,181 shares of Rocket Pharmaceutical, Inc. (the "Issuer")'s common stock, which will vest in equal monthly installments over a three-year period, such that all of the shares underlying this option will be fully vested on February 3, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.